Tazarotene
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
Tazarotene: From No UK Marketing Authorisation to Seborrheic Dermatitis
One-Sentence Summary
Tazarotene is a retinoid compound; however, this Evidence Pack contains no record of an approved original indication or UK marketing authorisation for this product. The TxGNN model predicts it may be effective for Seborrheic Dermatitis, but this direction is currently supported by only 1 clinical trial (assessed as low relevance) and no dedicated literature.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no UK marketing authorisation or approved indication text is on record for this product |
| Predicted New Indication | Seborrheic Dermatitis |
| TxGNN Prediction Score | 99.79% |
| Evidence Level | L5 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available in this Evidence Pack, and no approved UK indication or licensed product record exists for Tazarotene. Based on the information available, Tazarotene belongs to the retinoid class of compounds.
According to the repurposing rationale supplied with this prediction, Tazarotene, as a retinoid, may theoretically modulate keratinocyte differentiation, inhibit excessive epidermal proliferation, and exert anti-inflammatory effects — properties that could offer indirect benefit for the abnormal keratinisation and inflammatory changes seen in seborrheic dermatitis. However, the primary pathology of seborrheic dermatitis is driven by Malassezia yeast overgrowth and sebaceous gland dysfunction, which are not typical targets of retinoid therapy. Topical retinoids are also known to be irritant and could plausibly worsen the skin barrier disruption characteristic of this condition.
Overall, the mechanistic link is weak and the direction of effect is uncertain, which is consistent with the low evidence level assigned to this prediction.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT06281782 | Not Applicable | Unknown | 40 | Randomised trial comparing platelet-rich plasma plus topical retinoids versus topical retinoids alone in acne vulgaris; assessed as low relevance (grade C) — the study population and indication do not match seborrheic dermatitis, and the trial was included only because it involves a topical retinoid |
Literature Evidence
Currently no related literature available.
UK Market Information
No UK marketing authorisations are currently on record for Tazarotene; the product is not marketed in the United Kingdom.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence for the seborrheic dermatitis prediction is currently limited to model output (TxGNN score only), a single clinical trial judged of low relevance to the target indication, and no supporting literature. The proposed mechanistic link is also biologically weak, as the primary drivers of seborrheic dermatitis are not typical retinoid targets.
To proceed, the following is needed:
- UK product labelling/SmPC data, including warnings, contraindications, and prescribing information (currently a blocking data gap)
- Detailed mechanism of action (MOA) data from DrugBank or equivalent source (currently a high-severity data gap)
- Confirmation of UK marketing authorisation status, or evidence of an equivalent licensed product, before further evaluation
- Dedicated clinical trials or literature specifically evaluating Tazarotene in seborrheic dermatitis, rather than adjacent acne-vulgaris studies
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.